- Home
- SSTI vs CRDF Comparison
SSTI vs CRDF Comparison
Compare SSTI & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSTI
- CRDF
- Stock Information
- Founded
- SSTI 1996
- CRDF 1999
- Country
- SSTI United States
- CRDF United States
- Employees
- SSTI N/A
- CRDF N/A
- Industry
- SSTI Computer Software: Prepackaged Software
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SSTI Technology
- CRDF Health Care
- Exchange
- SSTI Nasdaq
- CRDF Nasdaq
- Market Cap
- SSTI 196.6M
- CRDF 233.5M
- IPO Year
- SSTI 2017
- CRDF N/A
- Fundamental
- Price
- SSTI $12.69
- CRDF $4.15
- Analyst Decision
- SSTI Buy
- CRDF Strong Buy
- Analyst Count
- SSTI 8
- CRDF 6
- Target Price
- SSTI $20.38
- CRDF $11.92
- AVG Volume (30 Days)
- SSTI 65.5K
- CRDF 1.4M
- Earning Date
- SSTI 08-05-2025
- CRDF 08-07-2025
- Dividend Yield
- SSTI N/A
- CRDF N/A
- EPS Growth
- SSTI N/A
- CRDF N/A
- EPS
- SSTI N/A
- CRDF N/A
- Revenue
- SSTI $104,970,000.00
- CRDF $587,000.00
- Revenue This Year
- SSTI $11.41
- CRDF N/A
- Revenue Next Year
- SSTI $8.56
- CRDF N/A
- P/E Ratio
- SSTI N/A
- CRDF N/A
- Revenue Growth
- SSTI 7.65
- CRDF N/A
- 52 Week Low
- SSTI $9.33
- CRDF $2.01
- 52 Week High
- SSTI $19.43
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- SSTI 32.80
- CRDF 68.00
- Support Level
- SSTI $12.51
- CRDF $3.07
- Resistance Level
- SSTI $14.26
- CRDF $4.24
- Average True Range (ATR)
- SSTI 0.67
- CRDF 0.21
- MACD
- SSTI -0.09
- CRDF 0.07
- Stochastic Oscillator
- SSTI 15.35
- CRDF 95.76
About SSTI SoundThinking Inc.
SoundThinking Inc is a public safety technology company that combines transformative solutions and strategic advisory services for law enforcement and civic leadership. Its flagship SafetySmart platform includes ShotSpotter, the acoustic gunshot detection system, CrimeTracer, the foremost law enforcement search engine, CaseBuilder, a one-stop investigation management system, and ResourceRouter, software that directs patrol and community anti-violence resources to help maximize their impact.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.